Cranston Lynda Sarah 4
4 · DelMar Pharmaceuticals, Inc. · Filed Jul 1, 2019
Insider Transaction Report
Form 4
Cranston Lynda Sarah
Director
Transactions
- Other
Common Stock
2019-06-28+8→ 300 total(indirect: Held by J.G. Cranston & Associates, Inc.)
Footnotes (2)
- [F1]The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock.
- [F2]On May 8, 2019, the issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.